Rare Disease Theranostics Platform for Drug Candidate Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing new drugs are costly and time-consuming, especially for rare diseases, due to the need for extensive pharmacokinetic and safety data, leading to limited resources for investigating treatments for these diseases.
Innovation Solution
The development of rare disease theranostics platforms that include a cell-phenotype image-enhancing instrument, a drug/nutraceutical library, and a computer-implemented system for analyzing the response of optically-visible rare-disease cell phenotypes to drugs or nutraceuticals, allowing for the identification of candidates that normalize or partially normalize the cell phenotype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional drug development methods are used for rare diseases, then comprehensive pharmacokinetic and safety data can be obtained, but the process becomes costly and time-consuming
Solution Approach 1:
The patent performs preliminary phenotypic screening of drug candidates using patient-derived cells before conducting full pharmacokinetic and safety studies. By visualizing and selecting drugs that show beneficial phenotypic effects early in the development process, the system reduces the number of candidates that require extensive downstream testing, thereby reducing overall development time while maintaining data quality for selected candidates
Solution Approach 2:
The patent implements a staged approach where phenotypic screening provides partial evaluation data that is sufficient for initial candidate selection. This partial action (phenotypic screening alone) is used to filter candidates, and only promising candidates proceed to complete pharmacokinetic and safety evaluation, reducing the total workload and time required
2Reliability
If traditional drug development methods are used for rare diseases, then thorough safety evaluation can be conducted, but the cost increases significantly
Solution Approach 1:
The patent divides the drug evaluation process into distinct segments: phenotypic screening using patient-derived cells, followed by pharmacokinetic studies, and then safety evaluation. This segmentation allows the system to identify and advance only those candidates showing beneficial phenotypic effects, reducing the number of drugs that require expensive safety studies while maintaining thorough evaluation for selected candidates
Solution Approach 2:
The patent uses phenotypic screening as a partial evaluation method that provides sufficient information for candidate selection without requiring complete safety evaluation. This partial action reduces the number of candidates proceeding to costly safety studies, thereby reducing overall development cost while maintaining safety evaluation quality for advanced candidates
3Reliability
If extensive pharmacokinetic and safety data collection is performed, then drug approval can be achieved, but resources for investigating treatments for rare diseases are limited
Solution Approach 1:
The patent performs preliminary phenotypic screening to identify promising drug candidates before committing resources to extensive pharmacokinetic and safety studies. This preliminary filtering increases the likelihood of success for candidates that do proceed through the full data collection process, improving resource efficiency and enabling more treatments to be investigated with limited resources
Solution Approach 2:
The patent segments the resource-intensive data collection process into stages, with phenotypic screening serving as a low-resource filter. This segmentation ensures that extensive pharmacokinetic and safety data collection is performed only on candidates with demonstrated phenotypic benefit, improving the productivity of treatment investigation by reducing wasted resources on ineffective candidates
4Measurement precision
If phenotypic responses are visualized using traditional methods, then cell responses can be observed, but the speed and efficiency of candidate identification is reduced
Solution Approach 1:
The patent replaces traditional manual phenotypic observation methods with automated optical imaging and computerized image analysis systems. This substitution maintains measurement precision by using standardized imaging protocols and automated analysis algorithms, while dramatically increasing productivity by enabling high-throughput screening of multiple drug candidates simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables fast, cost-effective identification of drug or nutraceutical candidates for rare diseases by visualizing phenotypic responses and whole-cell effects, reducing the time and number of assays needed, and creating personalized treatment protocols.
Implementation Method 1
a cell-phenotype image-enhancing instrument... detects the response of the optically-visible rare-disease cell-phenotype
Implementation Method 2
magnification optics having sufficient magnifying power to visualize one cell in a plurality of cells
Data Source
AI summary
Theranostics platforms for identifying drugs and nutraceuticals for treatment of rare disease are described. The platforms comprise (a) a cell-phenotype image-enhancing instrument; (b) a drug/nutraceutical library; and (c) a computer-implemented system for analyzing a response of an optically-visible rare-disease cell phenotype to a drug or nutraceutical from the drug/nutraceutical library.